Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses.
anaplastic thyroid carcinoma
core needle biopsy
fine needle aspiration cytology
poorly differentiated thyroid carcinoma
thyroid lymphoma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
01
2022
accepted:
10
03
2022
entrez:
25
4
2022
pubmed:
26
4
2022
medline:
26
4
2022
Statut:
epublish
Résumé
Large thyroid masses, particularly if rapidly growing, are often characterized by compression and infiltration of the vital structures of the neck. Therefore, an early and precise diagnosis, not only of malignancy but also of histotype, is mandatory to set up the right therapy. The aim of this study was to evaluate the diagnostic performance of fine needle aspiration cytology (FNAC) and core needle biopsy (CNB) in this setting. We prospectively evaluated 95 patients with large and rapidly growing thyroid masses admitted to the University Hospital of Pisa between April 2014 and January 2020. All patients were submitted to FNAC and CNB in the same session. The ability of both procedures to diagnose the malignancy of the lesions, particularly the histotype, and to obtain sufficient material to perform molecular analysis was evaluated. FNAC obtained adequate tumor sample to reach a diagnosis in 76 of 95 (80%) patients, while a higher percentage was obtained with CNB (92/95, 96.8%). FNAC was able to identify the malignancy of the lesion in 74 of 95 (77.9%) cases, but only in 16 of 74 (21.6%) cases was it able to define the histotype. CNB was able to define the malignancy of the lesion in all but three cases (92/95, 96.8%), and in all specimens, the histotype was identified. Moreover, in all cases, the material extracted from CNB was optimal to perform molecular analysis. No surgery-related complications were experienced with both procedures. CNB is a rapid and safe procedure with higher performance compared to FNAC in identifying the histotype of large and rapidly growing thyroid masses. Moreover, adequate material can be obtained to characterize the molecular profile for the treatment of potentially lethal cancers. In the era of precision medicine, CNB should be introduced in routine clinical practice as a key procedure for an early diagnosis and therapy of these diseases.
Sections du résumé
Background
UNASSIGNED
Large thyroid masses, particularly if rapidly growing, are often characterized by compression and infiltration of the vital structures of the neck. Therefore, an early and precise diagnosis, not only of malignancy but also of histotype, is mandatory to set up the right therapy. The aim of this study was to evaluate the diagnostic performance of fine needle aspiration cytology (FNAC) and core needle biopsy (CNB) in this setting.
Patients and Methods
UNASSIGNED
We prospectively evaluated 95 patients with large and rapidly growing thyroid masses admitted to the University Hospital of Pisa between April 2014 and January 2020. All patients were submitted to FNAC and CNB in the same session. The ability of both procedures to diagnose the malignancy of the lesions, particularly the histotype, and to obtain sufficient material to perform molecular analysis was evaluated.
Results
UNASSIGNED
FNAC obtained adequate tumor sample to reach a diagnosis in 76 of 95 (80%) patients, while a higher percentage was obtained with CNB (92/95, 96.8%). FNAC was able to identify the malignancy of the lesion in 74 of 95 (77.9%) cases, but only in 16 of 74 (21.6%) cases was it able to define the histotype. CNB was able to define the malignancy of the lesion in all but three cases (92/95, 96.8%), and in all specimens, the histotype was identified. Moreover, in all cases, the material extracted from CNB was optimal to perform molecular analysis. No surgery-related complications were experienced with both procedures.
Conclusions
UNASSIGNED
CNB is a rapid and safe procedure with higher performance compared to FNAC in identifying the histotype of large and rapidly growing thyroid masses. Moreover, adequate material can be obtained to characterize the molecular profile for the treatment of potentially lethal cancers. In the era of precision medicine, CNB should be introduced in routine clinical practice as a key procedure for an early diagnosis and therapy of these diseases.
Identifiants
pubmed: 35463338
doi: 10.3389/fonc.2022.854755
pmc: PMC9022105
doi:
Types de publication
Journal Article
Langues
eng
Pagination
854755Informations de copyright
Copyright © 2022 Matrone, De Napoli, Torregrossa, Aghababyan, Papini, Ambrosini, Cervelli, Ugolini, Basolo, Molinaro, Elisei and Materazzi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ann Oncol. 2000 Sep;11(9):1083-9
pubmed: 11061600
Mod Pathol. 2019 Jan;32(Suppl 1):58-70
pubmed: 30600317
Surgery. 2001 Dec;130(6):1028-34
pubmed: 11742333
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Eur Radiol. 2017 Mar;27(3):1186-1194
pubmed: 27311538
J Clin Oncol. 2018 Jan 1;36(1):7-13
pubmed: 29072975
Thyroid. 2021 Mar;31(3):337-386
pubmed: 33728999
Mol Clin Oncol. 2021 Jan;14(1):1
pubmed: 33235729
N Engl J Med. 2020 Aug 27;383(9):825-835
pubmed: 32846061
Ultrasound Med Biol. 2018 Jun;44(6):1145-1154
pubmed: 29576248
Cancer Cytopathol. 2014 Oct;122(10):745-50
pubmed: 24913410
Otolaryngol Head Neck Surg. 2016 Apr;154(4):618-25
pubmed: 26908554
Thyroid. 2012 May;22(5):468-75
pubmed: 22304417
iScience. 2019 Oct 25;20:324-336
pubmed: 31605946
Cancer. 2005 Apr 1;103(7):1330-5
pubmed: 15739211
Endocr Pract. 2008 May-Jun;14(4):426-31
pubmed: 18558594
Diagn Cytopathol. 2002 Jul;27(1):1-4
pubmed: 12112806
Breast. 2017 Feb;31:157-166
pubmed: 27866091
J Am Soc Cytopathol. 2016 Mar - Apr;5(2):107-115
pubmed: 31042490
Endocr Pract. 2004 May-Jun;10(3):234-41
pubmed: 15310542
Cancer. 2001 Aug 25;93(4):263-8
pubmed: 11507700
Diagn Cytopathol. 2019 Dec;47(12):1245-1250
pubmed: 31411821
Thyroid. 2019 Aug;29(8):1036-1043
pubmed: 31319771
J Clin Invest. 2016 Mar 1;126(3):1052-66
pubmed: 26878173
Radiology. 2003 Mar;226(3):827-32
pubmed: 12601219
Cytojournal. 2009 Jan 19;6:1
pubmed: 19495405
Korean J Radiol. 2017 Jan-Feb;18(1):217-237
pubmed: 28096731
Laryngoscope. 2018 Jan;128(1):118-125
pubmed: 28699165
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
Lancet Diabetes Endocrinol. 2021 Aug;9(8):491-501
pubmed: 34118198
Thyroid. 2021 Jul;31(7):1076-1085
pubmed: 33509020
JAMA Oncol. 2020 Sep 1;6(9):1397-1404
pubmed: 32761153
J Endocrinol Invest. 2014 Jun;37(6):593-9
pubmed: 24789536
Cancer Cytopathol. 2016 Jan;124(1):14-27
pubmed: 26348024
J Pathol Transl Med. 2020 Jan;54(1):64-86
pubmed: 31964112
Front Oncol. 2019 Dec 17;9:1390
pubmed: 31921647
Cancer. 2001 Oct 25;93(5):319-22
pubmed: 11668466
J Urol. 2017 Jun;197(6):1396-1402
pubmed: 28093293
Thyroid. 2018 Jan;28(1):79-87
pubmed: 29161986
Eur Radiol. 2016 Apr;26(4):1031-6
pubmed: 26201291
J Cardiothorac Surg. 2013 May 17;8:131
pubmed: 23684153
Thyroid. 1998 Aug;8(8):715-26
pubmed: 9737368
Br J Oral Maxillofac Surg. 2016 Apr;54(3):260-5
pubmed: 26837638
J Clin Endocrinol Metab. 2012 Aug;97(8):2566-72
pubmed: 22869844
Cancers (Basel). 2021 Feb 22;13(4):
pubmed: 33671494
Ann Surg Oncol. 2017 Jun;24(6):1533-1539
pubmed: 27873099
Nat Rev Endocrinol. 2017 Nov;13(11):644-660
pubmed: 28707679
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Head Neck. 2012 Oct;34(10):1497-503
pubmed: 22127851
Adv Anat Pathol. 2018 Nov;25(6):413-429
pubmed: 30157042
Thyroid. 2017 Jun;27(6):751-756
pubmed: 28463585
Am J Clin Pathol. 1985 Feb;83(2):135-58
pubmed: 2578727